Female patients must either be of non reproductive potential or must have a negative serum pregnancy test within 14 days prior to the administration of study drug. Childbearing potential women must have agreed to use one barrier method of contraception, such as condom, plus an additional highly effective method of contraception during treatment on this trial an for up to 6 month after the last dose of study treatment
Sexually active males patients must agree to use condom during the clinical investigation and for at least 6 months after the study treatment. Also, it is recommended the childbearing potential female partner uses a highly effective method of contraception for the same duration
Written, dated and signed informed consent by the patient prior to any specific protocol procedure
Ability to comply with the protocol procedures
Patients must be affiliated to a social security system or beneficiary of the same
You may not be if
Patient who has already been treated or is currently being treated with the oral therapy studied
Grade 3 or 4 toxicity contraindicating the implementation of oral treatment, according to the NCI-CTCAE version 6.0
Patient unable to follow treatment program
Mental or psychological illness that does not allow the patient to give informed consent
Patient who has already benefited from specialized oncogeriatric care in the last 12 months
Patient who has already benefited from a pharmacological dosage for the oral therapy studied
Presence of a pathology or condition that makes the patient's participation in the study inappropriate which includes serious unresolved or unstable toxicities from previous administration of another investigational treatment or any medical condition that could interfere with patient safety, obtaining consent, or compliance with study procedures
Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
Clareo Health | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.
